Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of Liothyronine Versus Levothyroxine
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
CONTEXT: Levothyroxine (L-T(4)) therapy is based on the assumption that the conversion of T(4) into T(3) provides adequate amounts of active hormone at target tissues. However, in rodents, L-T(4) alone does not restore a euthyroid state in all tissues. Previous combination L-T(4)/liothyronine (L-T(3)) therapy trials focused on quality-of-life endpoints, and limited information is available on the effects on other measures of thyroid hormone action. OBJECTIVE: Our objective was to evaluate the efficacy of thyroid hormone replacement with L-T(4) or L-T(3) at doses producing equivalent normalization of TSH. PARTICIPANTS, DESIGN, AND SETTING: Fourteen hypothyroid patients participated in this randomized, double-blind, crossover intervention at the National Institutes of Health Clinical Center. INTERVENTIONS: L-T(3) or L-T(4) were administered thrice daily to achieve a target TSH from 0.5-1.5 mU/liter. Volunteers were studied as inpatients after 6 wk on a stable dose and at the target TSH. MAIN OUTCOME MEASURES: Serum thyroid hormones, lipid parameters, and indices of glucose metabolism were evaluated. RESULTS: No difference was observed in TSH between L-T(3) and L-T(4) treatments. L-T(3) resulted in significant weight loss [L-T(4), 70.6 ± 12.5, vs. L-T(3), 68.5 ± 11.9 kg (P = 0.009)] and in a 10.9 ± 10.0% decrease in total cholesterol (P = 0.002), 13.3 ± 12.1% decrease in low-density lipoprotein-cholesterol (P = 0.002), and an 18.3 ± 28.6% decrease in apolipoprotein B (P = 0.018). No significant differences were observed in high-density lipoprotein-cholesterol, heart rate, blood pressure, exercise tolerance, or insulin sensitivity. CONCLUSIONS: The substitution of L-T(3) for L-T(4) at equivalent doses (relative to the pituitary) reduced body weight and resulted in greater thyroid hormone action on the lipid metabolism, without detected differences in cardiovascular function or insulin sensitivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LT3 monotherapy administered three times daily produces stable TSH levels with continued fluctuations in T3 levels, such that they reach the upper end of the normal range with each of the three dose administrations (75,76).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“Moreover, as judged by the length of time that it took over the course of the study to reach and maintain the goal TSH, it is too frequent a dosing regimen for participants to easily adhere to.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“Sex hormone-binding globulin was also significantly increased, reflecting the hepatic impact of LT3 (75).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“Treatment with LT3 alone was associated with lowered total and low-density lipoprotein cholesterol and decreased body weight, presumably reflecting the action of T3 on lipid and energy metabolism.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
In the citing paper
“A crossover design is appealing because of the increase in statistical power due to the ability to perform paired analyses, as has been performed in prior studies (23,46,50,52,58,59,75,76,107).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [75]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Gharib, H., Papini, E., Paschke, R., Duick, D. S., Valcavi, R., Hegedüs, L., Vitti, P., Gharib, H., Papini, E., Paschke, R., et al. (2010) · Endocrine Practice · doi:10.4158/10024.gl · Cited by 1,088
Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling1
Gereben, B., Zavacki, A. M., Ribich, S., Kim, B. W., Huang, S. A., Simonides, W. S., Zeöld, A., & Bianco, A. C. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0019 · Cited by 891 · cited 2×
“This is not surprising because type-2 deiodinase (30) is particularly active in the thyrotroph, and it is thought to play a major role in the hypothalamuspituitary-thyroid axis (27, 31).”
BackgroundThe modification of diet in renal disease study group
Beck, G. J., Berg, R. L., Coggins, C. H., Gassman, J. J., Hunsicker, L. G., Schluchter, M. D., & Williams, G. W. (1991) · Controlled Clinical Trials · doi:10.1016/0197-2456(91)90069-x · Cited by 818
Gharib, H., Papini, E., Valcavi, R., Baskin, H. J., Crescenzi, A., Dottorini, M. E., Duick, D. S., Guglielmi, R., Hamilton, C. R., Zeiger, M. A., et al. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.63 · Cited by 681
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 1×
“tion within the normal laboratory reference limits (12).”
Background
Cited by
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Self-citationGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“A potential role for L-triiodothyronine monotherapy in lieu of L-thyroxine monotherapy was recently raised by a small randomized, double-blind crossover intervention study done comparing L-triiodothyronine monotherapy with L-thyroxine monotherapy in patients with hypothyroidism (298).”
Mechanisms of thyroid hormone action
Brent, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60047 · Cited by 1,244
“Interestingly, providing hypothyroid human subjects with only T3 rather than T4, but keeping their TSH in the normal reference range, also results in reduced LDL cholesterol and slight weight loss (120).”
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Metadata
- Authors
- Celi, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., & Pucino, F.
- Affiliations
- National Institutes of Health (US)
- National Heart, Lung, and Blood Institute (US)
- Corresponding author
- Celi, Francesco S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-11
- Volume
- 96
- Issue
- 11
- Pages
- 3466-3474
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3205882
- OpenAlex
- W2057697685
- Cited by
- 125
- References
- 48
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 8 · 2015: 3 · 2014: 13 · 2013: 11 · 2012: 13
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01-DK047057-02, Z01DK047057)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- liothyronine, levothyroxine, hypothyroidism, thyroid hormone replacement, lipid metabolism, cholesterol, apolipoprotein B, weight loss, insulin sensitivity, thyroid-stimulating hormone, cardiovascular function, exercise tolerance, glucose metabolism, thyroid hormone action, crossover trial, apolipoprotein A-I, apolipoprotein C
- MeSH terms
- Adult, Aged, Apolipoproteins B, Body Composition, Cholesterol, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypothyroidism, Male, Middle Aged, Quality of Life, Thyroid Hormones, Thyroxine, Triiodothyronine, Bone Density, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of Liothyronine Versus Levothyroxine. https://app.cochat.ai/papers/10.1210/jc.2011-1329
- The paper
- Celi, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., & Pucino, F. (2011). Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of Liothyronine Versus Levothyroxine. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-1329
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.